Game On: Revance Therapeutics Initiates Phase 3 Trial of Topical Botox
Will Revance's RT001 be the first topically neurotoxin treatment?
Tag: Revance
All
PopularAll
Latest
Revance Replaces Lidocaine with Mepivacaine in RHA Filler Line
Revance announces the U.S. launch of the Teoxane RHA Collection with mepivacaine, replacing lidocaine as the anesthetic in its dermal filler products.
All
Latest
Long-Term Data Shows Sustained Skin Clearance in Psoriasis with FDA-Approved Biologic
Study results presented at EADV 2025 show nearly half of initial complete responders maintained clearance over four years.
Revance and Mylan to Advance Development Program for Biosimilar to BOTOX
Revance Therapeutics Inc and Mylan NV announce Mylan’s decision to move forward with a development plan, under a 351(k) pathway, for a proposed biosimilar to BOTOX and BOTOX Cosmetic (onabotulinumtoxinA), according to a media release.
Read MoreRevance Therapeutics Inc Announces Study Results and a License Agreement for RT002
Revance Therapeutics Inc, a Newark, Calif-based developer of neuromodulators for the treatment of aesthetic and therapeutic conditions, announces two pieces of company news regarding RT002.
Read MoreHot Stuff: November 2015
JUVEDERM ULTRA XC for lips and Coolscupting’s new Coolmini for the double chin are among November’s “Hot Stuff.”
Read More